Faculté de Médecine
1, rue Gaston Veil
89 articles with OSE Immunotherapeutics
7/26/2021It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.
OSE Immunotherapeutics SA today announced a voluntary and temporary pause of enrollment and dosing in its ongoing Phase 1 clinical trial for CoVepiT, the company’s investigational prophylactic COVID-19 vaccine candidate.
OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
OSE Immunotherapeutics announced a €10 million payment corresponding to the first tranche of the financing granted by the European Investment Bank.
OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
OSE Immunotherapeutics and Cenexi, a French contract development and manufacturing organization, announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics' vaccine candidate against COVID-19 currently in Phase 1 clinical trial, which will be used in the product’s development phases.
OSE Immunotherapeutics announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.
OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) today announced that the Italian Medicines Agency (AIFA) and the Italian Ethics Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in combination with Opdivo® or chemotherapy as second-line treatment in patients with metastatic non-small cell lung cancer (NSCLC).
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
OSE Immunotherapeutics announced that the first healthy volunteer has been enrolled and dosed in the Phase 1 clinical trial evaluating its COVID-19 vaccine, named CoVepiT.
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
BI 765063, a first-in-class SIRPα inhibitor on the SIRPα/CD47 “Don’t eat me” pathway, is undercollaborative development with Boehringer Ingelheim.
OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1 Clinical Phase
CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging SARS-CoV-2 variants.
According to Teo, the definition of the next pandemic depends a lot on one’s perspective.
OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104
Agreement expands Veloxis’ product portfolio and the continued commitment to improving the lives of transplant patients. OSE Immunotherapeutics to receive up to €315 million in potential milestones, including a €7 million upfront, and tiered royalties on sales.
OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
OSE Immunotherapeutics announced the first peer-reviewed publication on OSE-230, a novel and innovative approach in the management of the resolution of chronic and severe inflammation, in Science Advances.
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
CoVepiT is a SARS-COV-2 vaccine activating T cell defenses through CD8 T-cell multi-epitope* responses. CoVepiT epitopes are selected from 11 viral protein targets and designed to cover all initial and new emerging SARS-CoV-2 variants.
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2020 and provided an update on key achievements, as well as the Company’s outlook for 2021 for its immunotherapies in T-cell vaccines, immuno-oncolog
OSE Immunotherapeutics and ARCAGY - GINECO Announce Initiation of a Randomized Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
OSE Immunotherapeutics and the French cooperative group ARCAGY-GINECO announced that the French National Agency for Medicines and Health Products Safety and the French Central Ethic Committee approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer.
OSE Immunotherapeutics to Present New Data Reflecting Expansion and Progress on its Immuno-Oncology and Inflammation Preclinical Portfolio at the 2021 AACR Annual meeting
CLEC-1, novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and tumor antigen cross-presentation. BiCKI ® -IL-7, bifunctional therapy targeting PD-1 and IL-7 to sustain exhausted T cell function and to disarm Treg suppressive activity.
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that Alexis Peyroles, Chief Executive Officer, will provide an overview of the Company’s business at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-11, 2021.
OSE Immunotherapeutics Announces Granting of First European Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127/S95011Covers therapeutic applications of OSE-127/S95011 through 2037
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that it has strengthened intellectual property rights for its anti-interleukin-7 receptor (IL-7R) antagonist OSE-127/S95011 through the granting of a first patent by the European Patent Office (EPO). The patent covers the product and its therapeutic applications in autoimmune and inflammatory diseases through 2037.
OSE Immunotherapeutics Enters a Loan Agreement of up to €25 Million with the European Investment Bank
This loan will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in diseases with high unmet medical needs,
OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics
OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced a new collaboration agreement with MAbSilico, a deep technology innovative TechBio located in Tours, France, to use artificial intelligence (AI)-based software for therapeutic monoclonal antibody drug development.